Heart Failure: FNP Board Exam Essentials Made Simple

Pathophysiology · 8 min read · July 18, 2026

Heart Failure for the FNP Boards: Diagnosis, Classification, and Treatment Made Simple

Heart failure is one of the highest-yield cardiovascular topics for the AANP and ANCC FNP certification exams—and one of the most important conditions you will manage in primary care.

Board questions may ask you to:

Distinguish HFrEF from HFpEF
Interpret an ejection fraction
Recognize left- versus right-sided congestion
Select the appropriate diagnostic test
Interpret BNP or NT-proBNP
Identify guideline-directed medical therapy
Recognize acute decompensated heart failure
Provide appropriate patient education
Decide when a patient requires emergency evaluation or specialty referral

The key is to stop thinking of heart failure as a single disease with a single treatment. Heart failure is a clinical syndrome that can result from many different structural or functional cardiac abnormalities.

A patient may have impaired contraction, impaired relaxation, abnormal filling pressures, valvular disease, ischemic injury, arrhythmia, or a combination of several problems.

Let’s organize it into the patterns you need to recognize.

What Is Heart Failure?

Heart failure is a clinical syndrome caused by a structural or functional cardiac abnormality that impairs ventricular filling, ventricular ejection, or both.

The result may include:

Reduced cardiac output
Elevated intracardiac filling pressures
Pulmonary congestion
Systemic venous congestion
Inadequate perfusion
Neurohormonal activation
Progressive cardiac remodeling

The heart has not necessarily “stopped,” and heart failure does not always mean that the ejection fraction is reduced.

Some patients have a normal or near-normal ejection fraction but still develop heart-failure symptoms because the ventricle is stiff, filling pressures are elevated, or another abnormality limits effective cardiac function.

Board pearl: Heart failure can occur with a reduced, mildly reduced, preserved, or previously reduced ejection fraction.

Ejection Fraction: What Does It Actually Mean?

Ejection fraction, or EF, represents the percentage of blood in the left ventricle that is ejected during systole.

For example, an EF of 60% does not mean the heart is pumping 60% of the body’s blood. It means the left ventricle ejects approximately 60% of the blood it contains at the end of diastole.

A normal EF does not automatically exclude heart failure. EF measures one aspect of systolic function; it does not directly measure ventricular relaxation, filling pressure, valve function, or overall cardiac performance.

The Four Ejection-Fraction Categories

Current heart-failure classification includes four EF categories:

Heart-failure category	Ejection fraction	Key concept
HFrEF	40% or less	Reduced systolic function
HFmrEF	41%–49%	Mildly reduced EF
HFpEF	50% or greater	Preserved EF with evidence of increased filling pressures
HFimpEF	Previous EF 40% or less, now greater than 40%	EF has improved with treatment

This classification is emphasized in the current AHA/ACC/HFSA guideline framework. 2022 AHA/ACC/HFSA Heart Failure Guideline

1. HFrEF: Heart Failure With Reduced Ejection Fraction

HFrEF was traditionally called systolic heart failure.

What is happening?

The left ventricle has impaired contractility and cannot eject blood effectively. The ventricle may become enlarged and undergo adverse remodeling.

Ejection fraction

[ \text{EF} \leq 40% ]

Common causes

Coronary artery disease
Previous myocardial infarction
Dilated cardiomyopathy
Chronic uncontrolled hypertension
Myocarditis
Cardiomyopathy related to alcohol or cardiotoxic medications
Significant valvular disease
Tachycardia-mediated cardiomyopathy
Peripartum cardiomyopathy
Genetic cardiomyopathy

Typical manifestations

Patients may develop symptoms from both congestion and reduced cardiac output:

Dyspnea
Orthopnea
Paroxysmal nocturnal dyspnea
Fatigue
Reduced exercise tolerance
Peripheral edema
Rapid weight gain
Pulmonary crackles
Elevated jugular venous pressure
Cool extremities or poor perfusion in advanced disease

Memory aid: HFrEF has a pumping problem—the ventricle cannot contract effectively.

2. HFmrEF: Heart Failure With Mildly Reduced Ejection Fraction

HFmrEF describes symptomatic heart failure with an EF between 41% and 49%.

This category should not be dismissed as “almost normal.” These patients may have significant symptoms, elevated filling pressures, and cardiovascular risk.

Causes and presentation

HFmrEF may occur in patients:

Recovering from a previously lower EF
Progressing toward reduced EF
With ischemic heart disease
With hypertension
With cardiomyopathy
With multiple cardiometabolic conditions

Management often resembles HFrEF treatment, especially when the EF is closer to 40% or the patient previously had HFrEF.

3. HFpEF: Heart Failure With Preserved Ejection Fraction

HFpEF was traditionally called diastolic heart failure.

What is happening?

The left ventricle may contract adequately but relaxes or fills abnormally. The ventricle is often stiff and noncompliant, causing filling pressures to rise.

Ejection fraction

[ \text{EF} \geq 50% ]

A preserved EF alone does not diagnose HFpEF. The patient must also have symptoms and signs consistent with heart failure plus evidence supporting elevated filling pressures or structural heart disease.

Common risk factors and associated conditions

Long-standing hypertension
Left ventricular hypertrophy
Older age
Obesity
Type 2 diabetes
Chronic kidney disease
Atrial fibrillation
Coronary artery disease
Sleep apnea
Valvular disease
Infiltrative or restrictive cardiomyopathy

Presentation

Patients may have:

Exertional dyspnea
Exercise intolerance
Orthopnea
Paroxysmal nocturnal dyspnea
Edema
Elevated jugular venous pressure
Pulmonary congestion
Abdominal fullness

Symptoms may be very similar to those of HFrEF.

Memory aid: HFpEF has a filling problem—the ventricle cannot relax and fill without elevated pressure.

4. HFimpEF: Heart Failure With Improved Ejection Fraction

HFimpEF describes a patient who previously had an EF of 40% or less and later demonstrates an EF above 40%.

This does not necessarily mean the heart failure has been permanently cured.

The improvement may reflect a successful response to:

Guideline-directed medical therapy
Revascularization
Treatment of an arrhythmia
Removal of a cardiotoxic exposure
Recovery from myocarditis or another reversible cause

Critical treatment principle

Guideline-directed therapy should generally be continued even after the EF improves because discontinuation may lead to relapse.

Board pearl: An improved EF is not a reason to automatically stop heart-failure therapy.

Left-Sided vs. Right-Sided Heart Failure

Heart failure is also described according to the side of the heart predominantly affected.

Left-sided heart failure

When the left ventricle cannot manage blood returning from the lungs, pressure backs up into the pulmonary circulation.

Common manifestations

Dyspnea on exertion
Orthopnea
Paroxysmal nocturnal dyspnea
Pulmonary crackles
Hypoxemia
Cough
Pulmonary edema
Fatigue
S3 gallop, particularly with volume overload and reduced EF

Memory aid: Left-sided failure backs up into the lungs.

Right-sided heart failure

When the right ventricle cannot move blood effectively through the pulmonary circulation, pressure backs up into the systemic venous system.

Common manifestations

Peripheral edema
Elevated jugular venous pressure
Hepatomegaly
Hepatojugular reflux
Ascites
Abdominal discomfort or fullness
Weight gain
Dependent edema
Possible hepatic congestion

The most common cause of right-sided heart failure is left-sided heart failure. Other causes include:

Pulmonary hypertension
Chronic lung disease
Right ventricular infarction
Tricuspid valve disease
Congenital heart disease

Memory aid: Right-sided failure backs up into the rest of the body.

Many patients eventually demonstrate findings of both left- and right-sided failure.

High-Yield Heart-Failure Symptoms

Dyspnea on exertion

Shortness of breath with activity is common but nonspecific. It may also occur with:

COPD
Asthma
Anemia
Obesity
Deconditioning
Pulmonary embolism
Interstitial lung disease
Ischemia

Orthopnea

Orthopnea is dyspnea that develops when lying flat and improves when the patient sits upright.

A common history question is:

“How many pillows do you use to sleep comfortably?”

Needing more pillows than usual or sleeping in a recliner may indicate worsening pulmonary congestion.

Paroxysmal nocturnal dyspnea

PND is sudden nighttime breathlessness that awakens the patient after they have been lying down. The patient may need to sit or stand to breathe comfortably.

PND is more specific for heart failure than general exertional dyspnea.

Rapid weight gain

A gain of several pounds over a short period may reflect fluid accumulation rather than increased body fat.

Fatigue and exercise intolerance

These may result from reduced cardiac output, skeletal-muscle changes, anemia, deconditioning, sleep disorders, or medication effects.

Physical Examination Findings

Important findings include:

Tachycardia
Tachypnea
Hypoxemia
Elevated jugular venous pressure
Pulmonary crackles
S3 gallop
Displaced point of maximal impulse
Peripheral edema
Hepatomegaly
Ascites
Cool extremities
Delayed capillary refill
Altered mentation in severe hypoperfusion

Important caution

The absence of crackles does not exclude heart failure. Patients with chronic heart failure may have significant congestion without obvious pulmonary crackles.

Peripheral edema is also not specific to heart failure. Consider:

Chronic venous insufficiency
Medication effects
Kidney disease
Liver disease
Lymphedema
Deep vein thrombosis
Hypoalbuminemia

Diagnosing Heart Failure

Heart failure should not be diagnosed from one symptom, one laboratory value, or one chest X-ray.

The evaluation usually includes:

History and physical examination
Electrocardiogram
Laboratory testing
Natriuretic peptide measurement when appropriate
Chest imaging when clinically indicated
Transthoracic echocardiography
Evaluation for the underlying cause

The Most Important Initial Imaging Test

A transthoracic echocardiogram is central to the evaluation of suspected heart failure.

It provides information about:

Ejection fraction
Chamber size
Ventricular wall thickness
Regional wall-motion abnormalities
Valve structure and function
Right ventricular function
Diastolic function
Estimated pulmonary pressures
Pericardial disease

Board pearl: Echocardiography is the key test for classifying heart failure according to ejection fraction and evaluating cardiac structure and function.

BNP and NT-proBNP

B-type natriuretic peptide and N-terminal pro-BNP are released in response to myocardial wall stress.

They can support the diagnosis of heart failure in a patient with dyspnea, particularly when the diagnosis is uncertain.

Higher values may occur with:

Heart failure
Older age
Chronic kidney disease
Atrial fibrillation
Acute coronary syndrome
Pulmonary hypertension
Pulmonary embolism
Critical illness

Lower values may occur with:

Obesity
Early or well-treated heart failure
Some cases of HFpEF

A normal or low natriuretic peptide level makes significant heart failure less likely, but the result must be interpreted in context.

Do not diagnose heart failure solely from an elevated BNP, especially in a patient with chronic kidney disease or atrial fibrillation.

Medication effect

Sacubitril inhibits neprilysin, which affects BNP metabolism. NT-proBNP is often more useful for serial assessment in patients taking sacubitril/valsartan because NT-proBNP is not a neprilysin substrate in the same way.

Board pearl: BNP supports the diagnosis, but echocardiography classifies the heart failure.

Additional Diagnostic Testing

Depending on the presentation, the initial workup may include:

Complete blood count
Comprehensive metabolic panel
Serum creatinine and eGFR
Electrolytes
Liver function tests
Thyroid-stimulating hormone
Urinalysis
Lipid profile
Hemoglobin A1C
Iron studies
Troponin when acute ischemia or myocardial injury is suspected
Chest radiograph
Electrocardiogram

The evaluation should also look for the underlying cause and factors that may worsen heart failure.

Chest X-Ray Findings

A chest radiograph may show:

Cardiomegaly
Pulmonary vascular congestion
Interstitial edema
Alveolar edema
Kerley B lines
Pleural effusions

A normal chest radiograph does not completely exclude heart failure, particularly chronic or early disease.

Common Causes and Precipitants

Heart failure may develop or worsen because of:

Coronary artery disease
Myocardial infarction
Uncontrolled hypertension
Valvular disease
Cardiomyopathy
Myocarditis
Atrial fibrillation or another arrhythmia
Thyroid disease
Alcohol or stimulant use
Cardiotoxic medications
Congenital heart disease
Peripartum cardiomyopathy
Infiltrative disease

Common triggers of acute decompensation

Remember that a patient with stable chronic heart failure can deteriorate because of a new trigger.

Common precipitants include:

Medication nonadherence
High sodium intake
Excess fluid intake
Myocardial ischemia or infarction
Uncontrolled hypertension
Atrial fibrillation with rapid ventricular response
Infection
Acute kidney injury
Pulmonary embolism
Anemia
Thyroid dysfunction
NSAID use
Thiazolidinedione use
Negative-inotropic medications in susceptible patients
Excessive alcohol or illicit stimulant use

Board pearl: When heart failure suddenly worsens, identify and treat the precipitating cause—not just the congestion.

The Four Pillars of HFrEF Treatment

Modern guideline-directed medical therapy for symptomatic chronic HFrEF includes four foundational medication classes:

An ARNI, ACE inhibitor, or ARB
An evidence-based beta-blocker
A mineralocorticoid receptor antagonist
An SGLT2 inhibitor

The AHA/ACC/HFSA guideline identifies four core medication classes for HFrEF, including SGLT2 inhibitors. AHA Guideline Summary

These medications are used not merely to improve symptoms. When appropriately prescribed, they reduce hospitalization, disease progression, and mortality.

Pillar 1: ARNI, ACE Inhibitor, or ARB

Preferred option: ARNI

The primary ARNI used in HFrEF is:

Sacubitril/valsartan

Sacubitril inhibits neprilysin, increasing beneficial natriuretic peptides, while valsartan blocks the angiotensin II receptor.

Potential benefits include:

Reduced mortality
Reduced heart-failure hospitalization
Improved clinical outcomes

Important adverse effects

Hypotension
Hyperkalemia
Kidney dysfunction
Angioedema

Critical washout rule

Do not administer sacubitril/valsartan within 36 hours of an ACE inhibitor because of the increased risk of angioedema.

Board pearl: ACE inhibitor to ARNI requires a 36-hour washout.

ACE inhibitors

Examples include:

Lisinopril
Enalapril
Ramipril

Important adverse effects include:

Cough
Hyperkalemia
Increased creatinine
Hypotension
Angioedema

ACE inhibitors are contraindicated during pregnancy and should not be used in a patient with a history of ACE inhibitor–associated angioedema.

ARBs

Examples include:

Valsartan
Losartan
Candesartan

ARBs may be used when an ACE inhibitor causes cough, although a history of angioedema requires careful individualized assessment.

Do not routinely combine an ACE inhibitor with an ARB.

Pillar 2: Evidence-Based Beta-Blockers

Only three beta-blockers have established mortality benefit in HFrEF:

Carvedilol
Metoprolol succinate
Bisoprolol

Metoprolol tartrate is not interchangeable with metoprolol succinate for guideline-directed HFrEF therapy.

Benefits

Reduced mortality
Reduced hospitalization
Improved ventricular function
Reduced sympathetic activation
Heart-rate control

Initiation principles

Begin when the patient is clinically stable and reasonably euvolemic. Start at a low dose and titrate gradually.

Do not newly initiate or aggressively increase a beta-blocker during severe acute decompensation, cardiogenic shock, or marked volume overload.

Adverse effects

Bradycardia
Hypotension
Fatigue
Dizziness
Possible worsening congestion during initiation
Bronchospasm in susceptible patients

Board pearl: HFrEF beta-blockers are carvedilol, metoprolol succinate, and bisoprolol.

Pillar 3: Mineralocorticoid Receptor Antagonists

Examples include:

Spironolactone
Eplerenone

Benefits

In appropriately selected patients with HFrEF, MRAs can reduce:

Mortality
Hospitalization
Disease progression

Important monitoring

Monitor:

Potassium
Creatinine
eGFR
Blood pressure

These medications can cause dangerous hyperkalemia, particularly in patients with significant kidney impairment or those taking other potassium-raising medications.

Spironolactone adverse effects

Spironolactone may cause:

Gynecomastia
Breast tenderness
Menstrual changes
Sexual adverse effects

Eplerenone has fewer antiandrogen effects but may be more expensive.

Board pearl: Before starting an MRA, think potassium and kidney function.

Pillar 4: SGLT2 Inhibitors

Examples include:

Dapagliflozin
Empagliflozin

SGLT2 inhibitors improve heart-failure outcomes even in patients who do not have diabetes.

Benefits

Reduced heart-failure hospitalization
Reduced cardiovascular events
Kidney protection in appropriate patients
Modest diuretic and blood-pressure effects

Important adverse effects and precautions

Genital mycotic infections
Volume depletion
Hypotension
Euglycemic diabetic ketoacidosis
Increased urination
Rare severe perineal infection

These medications should be held before scheduled surgery and during certain acute illnesses, prolonged fasting, dehydration, or other situations that increase ketoacidosis risk.

Board pearl: SGLT2 inhibitors are heart-failure medications—not merely diabetes medications.

Additional HFrEF Medications

Loop diuretics

Examples include:

Furosemide
Bumetanide
Torsemide

Loop diuretics reduce congestion and improve symptoms.

They can relieve:

Dyspnea
Pulmonary edema
Peripheral edema
Abdominal congestion

However, loop diuretics primarily provide symptomatic volume management. They are not one of the four foundational medication classes shown to provide the same mortality benefit.

Monitor for:

Hypokalemia
Hyponatremia
Hypomagnesemia
Volume depletion
Hypotension
Kidney dysfunction
Ototoxicity at high doses or with rapid IV administration

Board pearl: Diuretics help the patient feel better by removing excess fluid, but they do not replace disease-modifying therapy.

Hydralazine and isosorbide dinitrate

This combination may be used:

In selected self-identified Black patients with symptomatic HFrEF who remain symptomatic despite appropriate therapy
In patients who cannot use an ARNI, ACE inhibitor, or ARB because of intolerance, kidney dysfunction, or hyperkalemia

Adverse effects include:

Headache
Hypotension
Dizziness
Reflex tachycardia
Drug-induced lupus–like syndrome with hydralazine

Nitrates must not be combined with phosphodiesterase-5 inhibitors because of the risk of profound hypotension.

Ivabradine

Ivabradine may be considered for selected patients with:

Symptomatic stable HFrEF
EF of 35% or less
Sinus rhythm
Resting heart rate of at least 70 beats per minute
Appropriate beta-blocker therapy at the maximally tolerated dose

It lowers heart rate by inhibiting the funny current in the sinoatrial node.

It does not replace a guideline-directed beta-blocker.

Digoxin

Digoxin may reduce hospitalization in selected symptomatic patients despite guideline-directed therapy. It does not provide the same mortality benefit as the four foundational HFrEF classes.

Important toxicity findings include:

Nausea
Vomiting
Anorexia
Confusion
Weakness
Visual disturbances
Bradyarrhythmias
Ventricular arrhythmias

Digoxin toxicity risk increases with:

Kidney impairment
Hypokalemia
Older age
Drug interactions

Board pearl: Hypokalemia increases the risk of digoxin toxicity.

Treating HFpEF

HFpEF treatment differs from HFrEF treatment because therapies that clearly reduce mortality in HFrEF have not all shown the same benefit across preserved EF.

Management focuses on:

Relieving congestion
Treating hypertension
Managing atrial fibrillation
Treating coronary artery disease
Addressing obesity
Managing diabetes
Treating chronic kidney disease
Evaluating sleep apnea
Encouraging appropriate physical activity
Managing other contributing conditions

SGLT2 inhibitors

SGLT2 inhibitors have become an important treatment for patients with HFpEF because they reduce heart-failure hospitalization and improve outcomes across a broad range of EF.

Diuretics

Diuretics are used to manage symptomatic congestion, but excessive diuresis can reduce preload and cause:

Hypotension
Acute kidney injury
Dizziness
Worsening fatigue

Blood-pressure control

Hypertension is a major contributor to HFpEF and should be treated according to current targets and the patient’s comorbidities.

Atrial fibrillation

Atrial contraction contributes significantly to ventricular filling. Loss of atrial contraction and rapid ventricular rates may worsen symptoms in a stiff ventricle.

Management may include:

Rate or rhythm control
Anticoagulation based on thromboembolic risk
Treatment of precipitating factors

Board pearl: In HFpEF, think SGLT2 inhibitor, diuresis for congestion, blood-pressure control, and aggressive management of comorbidities.

Treating HFmrEF

Patients with HFmrEF may benefit from:

SGLT2 inhibitors
Diuretics for congestion
ARNI, ACE inhibitor, or ARB in selected patients
Evidence-based beta-blockers
Mineralocorticoid receptor antagonists

Treatment is individualized, with greater consideration of HFrEF-directed therapies when the EF is closer to 40% or was previously reduced.

Medications That Can Worsen Heart Failure

High-yield medications to recognize include:

NSAIDs

NSAIDs can cause:

Sodium retention
Fluid retention
Increased blood pressure
Reduced diuretic effectiveness
Worsening kidney function

Patients with heart failure should avoid routine NSAID use unless specifically directed by a clinician who has considered the risks.

Thiazolidinediones

Pioglitazone and rosiglitazone can cause fluid retention and worsen heart failure.

Certain calcium channel blockers

Non-dihydropyridine calcium channel blockers such as verapamil and diltiazem have negative inotropic effects and are generally avoided in HFrEF.

Amlodipine does not provide a heart-failure mortality benefit but is generally considered hemodynamically neutral when needed for another indication.

Other concerns

Depending on the patient, also consider:

Excessive sodium-containing medications
Cardiotoxic chemotherapy
Stimulants
Heavy alcohol consumption
Some antiarrhythmic medications
Drug combinations that increase potassium or impair kidney function

ACC/AHA Heart Failure Stages

The ACC/AHA stages describe disease progression. Patients generally move forward through the stages rather than backward.

Stage	Description
Stage A	At risk for HF without symptoms, structural disease, or abnormal biomarkers
Stage B	Pre-HF: no symptoms, but structural disease, abnormal cardiac function, or abnormal biomarkers
Stage C	Symptomatic HF: current or previous symptoms caused by structural heart disease
Stage D	Advanced HF with symptoms that interfere with daily life or recurrent hospitalization despite treatment

Stage A: At Risk

Examples include patients with:

Hypertension
Diabetes
Obesity
Coronary artery disease
Exposure to cardiotoxic medications
Family history of cardiomyopathy

There are no heart-failure symptoms or structural abnormalities yet.

The goal is prevention.

Stage B: Pre-Heart Failure

Patients do not have symptoms but may have:

Reduced EF
Left ventricular hypertrophy
Chamber enlargement
Valvular disease
Wall-motion abnormalities
Elevated filling pressures
Abnormal cardiac biomarkers in the appropriate setting

Board pearl: Stage B means structural or functional abnormality without current or previous heart-failure symptoms.

Stage C: Symptomatic Heart Failure

Patients have structural heart disease with current or previous heart-failure symptoms.

Most chronic heart-failure management questions involve Stage C.

Stage D: Advanced Heart Failure

Patients have severe symptoms, recurrent hospitalization, or progressive disease despite optimal therapy.

They may need:

Advanced heart-failure consultation
Mechanical circulatory support
Transplant evaluation
Advanced hemodynamic management
Palliative care
Hospice when consistent with prognosis and goals

The AHA/ACC/HFSA guideline recommends referral to a specialized heart-failure team for patients with advanced HF who wish to pursue survival-prolonging therapies. AHA Heart Failure Guideline

NYHA Functional Classification

The New York Heart Association classification describes the patient’s current functional limitation.

NYHA class	Functional limitation
Class I	No limitation with ordinary physical activity
Class II	Mild limitation; comfortable at rest, symptoms with ordinary activity
Class III	Marked limitation; comfortable at rest, symptoms with less-than-ordinary activity
Class IV	Symptoms at rest or with any physical activity

Do not confuse the two systems

ACC/AHA stages describe disease progression.
NYHA classes describe current symptom severity and functional limitation.

A patient’s NYHA class may improve or worsen over time. ACC/AHA stage does not usually move backward.

Acute Decompensated Heart Failure

Acute decompensated heart failure is a rapid development or worsening of heart-failure symptoms that requires urgent assessment.

Concerning findings include:

Severe dyspnea
Hypoxemia
Pulmonary edema
Inability to lie flat
Rapidly increasing edema or weight
Chest pain
Syncope
New arrhythmia
Confusion
Hypotension
Cool extremities
Reduced urine output
Signs of cardiogenic shock

A patient with severe respiratory distress, hypoxemia, chest pain, hypotension, altered mental status, or suspected cardiogenic shock requires emergency evaluation.

Initial priorities

Emergency management may include:

Airway and breathing support
Supplemental oxygen for hypoxemia
Noninvasive ventilation when appropriate
Intravenous loop diuretics for congestion
Vasodilator therapy in selected hypertensive patients
Treatment of myocardial ischemia
Management of arrhythmias
Identification of infection or another precipitating cause
Hemodynamic support in shock

Oxygen is not automatically required for every patient with heart failure. It is used when hypoxemia or respiratory distress is present.

Patient Education: What FNPs Must Teach

Daily weights

Teach patients to:

Weigh themselves every morning
Use the same scale
Wear similar clothing
Weigh after urinating and before eating
Record the result
Report rapid weight gain according to their individualized action plan

A commonly used alert threshold is approximately:

2–3 pounds in one day
5 pounds in one week

The specific threshold should be individualized by the treating clinician.

Sodium

Patients should understand that high sodium intake can increase fluid retention and worsen congestion.

Teach label reading and awareness of common high-sodium foods:

Processed meats
Canned soups
Fast food
Frozen prepared meals
Salty snacks
Restaurant foods
Sauces and seasonings

Avoid presenting one rigid sodium target as appropriate for every patient. Recommendations should be individualized.

Fluid intake

Fluid restriction is not required for every stable patient with heart failure. It may be appropriate in selected patients with:

Significant congestion
Hyponatremia
Advanced disease
Recurrent decompensation

Medication adherence

Patients should know:

The purpose of each medication
When to take it
What adverse effects to report
Why they should not stop therapy when they feel better
Which over-the-counter medications to avoid
When laboratory monitoring is needed

Activity

Stable patients should generally be encouraged to participate in appropriate physical activity or cardiac rehabilitation rather than remain sedentary.

Exercise recommendations must be individualized based on symptoms, functional capacity, and clinical stability.

Follow-Up and Monitoring

Primary care follow-up may include:

Symptom progression
Functional status
Daily weight trends
Blood pressure
Heart rate and rhythm
Volume status
Medication adherence
Sodium intake
Kidney function
Potassium
Other electrolytes
Adverse effects
Need for medication titration
Vaccination status
Depression and quality of life
Goals of care

Kidney function and electrolytes require particular attention after initiating or adjusting:

ACE inhibitors
ARBs
ARNIs
Mineralocorticoid receptor antagonists
Diuretics
SGLT2 inhibitors in selected circumstances

Board-Style Pattern Recognition

Pattern 1: Reduced EF

A patient with a previous MI has fatigue, orthopnea, edema, and an EF of 30%.

Diagnosis: HFrEF Core treatment concept: Four-pillar guideline-directed medical therapy plus diuretics when congested

Pattern 2: Preserved EF

An older patient with obesity, diabetes, atrial fibrillation, and long-standing hypertension has exertional dyspnea, elevated filling pressures, and an EF of 60%.

Diagnosis: HFpEF Management concept: SGLT2 inhibitor when appropriate, control congestion and blood pressure, and manage comorbidities

Pattern 3: Right-sided congestion

A patient has elevated JVP, hepatomegaly, ascites, and peripheral edema.

Clinical pattern: Systemic venous congestion consistent with right-sided heart failure

Pattern 4: ACE inhibitor transition

A patient taking lisinopril is being transitioned to sacubitril/valsartan.

Critical action: Allow a 36-hour washout after the ACE inhibitor

Pattern 5: Evidence-based beta-blocker

A patient with stable HFrEF requires a beta-blocker with established mortality benefit.

Appropriate choices: Carvedilol, metoprolol succinate, or bisoprolol

Pattern 6: Worsening after a new medication

A patient with heart failure develops rapid weight gain and edema after starting pioglitazone for diabetes.

Most likely cause: Thiazolidinedione-associated fluid retention

Pattern 7: Improved EF

A patient’s EF increases from 30% to 50% after treatment, and symptoms resolve.

Classification: HFimpEF Treatment principle: Continue guideline-directed therapy unless a specialist-directed reason exists to modify it

Common Board-Exam Traps

Trap 1: A normal EF excludes heart failure

Incorrect. HFpEF occurs with an EF of 50% or greater.

Trap 2: Every patient with edema has heart failure

Incorrect. Edema has many cardiac and noncardiac causes.

Trap 3: Diuretics are the entire treatment for HFrEF

Incorrect. Diuretics relieve congestion, but the four foundational HFrEF medication classes modify disease progression and improve outcomes.

Trap 4: Any beta-blocker is acceptable for HFrEF

Incorrect. The evidence-based choices are carvedilol, metoprolol succinate, and bisoprolol.

Trap 5: BNP alone diagnoses heart failure

Incorrect. BNP and NT-proBNP must be interpreted with the history, examination, kidney function, body size, rhythm, and cardiac imaging.

Trap 6: The patient feels better, so therapy can be stopped

Incorrect. Symptom improvement or improved EF usually does not eliminate the need for guideline-directed treatment.

Trap 7: Beta-blockers should be rapidly increased during severe congestion

Incorrect. Beta-blockers are initiated and titrated when the patient is clinically stable and reasonably euvolemic.

Trap 8: Oxygen is required for every heart-failure exacerbation

Incorrect. Oxygen is primarily indicated for hypoxemia or significant respiratory distress.

Final Heart Failure Checklist

Before taking your FNP boards, make sure you can answer these questions:

What EF defines HFrEF?
What EF range defines HFmrEF?
Can HF occur with a preserved EF?
What does HFimpEF mean?
What symptoms suggest pulmonary congestion?
What findings suggest systemic venous congestion?
What is the most important imaging study for classification?
What factors can raise or lower BNP?
What are the four pillars of HFrEF therapy?
Which three beta-blockers have established HFrEF benefit?
What washout is required between an ACE inhibitor and ARNI?
Which medications require potassium and kidney monitoring?
Which medication classes can worsen fluid retention?
What is the role of loop diuretics?
How do ACC/AHA stages differ from NYHA classes?
Which findings require emergency evaluation?
What should a patient monitor at home?

Heart failure becomes much easier when you organize it into five questions:

Is the patient stable or acutely decompensated?
Is congestion, hypoperfusion, or both present?
What is the ejection-fraction category?
What caused or precipitated the heart failure?
Which therapies improve symptoms, and which improve long-term outcomes?

Once you can answer those questions, you are no longer memorizing a list of medications. You are thinking through heart failure the way a safe primary care provider should.

Turn Heart Failure Knowledge Into Board-Exam Confidence

Heart failure questions often contain several answer choices that sound reasonable. The challenge is knowing which medication improves survival, which one primarily relieves congestion, which finding requires emergency escalation, and which treatment is appropriate for the patient’s EF.

The FNP Review helps you practice those distinctions through board-style questions, detailed rationales, clinical teaching, readiness tracking, and separate preparation pathways for the AANP and ANCC certification exams.

Because passing the boards requires more than memorizing that heart failure causes edema.

It requires understanding what is failing, why it is failing, and what you should do next.

This article is intended for educational and board-review purposes. Heart-failure treatment must be individualized according to current guidelines, ejection fraction, symptoms, comorbidities, kidney function, potassium, blood pressure, medication tolerance, and specialist recommendations.